Schapiro, Denis
Sokolov, Artem http://orcid.org/0000-0002-8056-0504
Yapp, Clarence http://orcid.org/0000-0003-1144-5710
Chen, Yu-An
Muhlich, Jeremy L. http://orcid.org/0000-0002-0811-637X
Hess, Joshua http://orcid.org/0000-0003-3776-1092
Creason, Allison L. http://orcid.org/0000-0001-5724-1276
Nirmal, Ajit J.
Baker, Gregory J. http://orcid.org/0000-0002-5196-3961
Nariya, Maulik K.
Lin, Jia-Ren http://orcid.org/0000-0003-4702-7705
Maliga, Zoltan
Jacobson, Connor A. http://orcid.org/0000-0002-0299-3451
Hodgman, Matthew W.
Ruokonen, Juha
Farhi, Samouil L. http://orcid.org/0000-0003-1359-4568
Abbondanza, Domenic
McKinley, Eliot T.
Persson, Daniel
Betts, Courtney
Sivagnanam, Shamilene
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Goecks, Jeremy http://orcid.org/0000-0002-4583-5226
Coffey, Robert J. http://orcid.org/0000-0002-2180-3844
Coussens, Lisa M. http://orcid.org/0000-0003-2389-1865
Santagata, Sandro
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U2C-CA233262, P30 CA06516, U54-CA225088, U2C-CA233262, 1K99CA256497-01)
Ludwig Institute for Cancer Research
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2ZHP3_181475)
Damon Runyon Cancer Research Foundation (DRQ-03-20)
Article History
Received: 15 March 2021
Accepted: 22 September 2021
First Online: 25 November 2021
Competing interests
: P.K.S. is a member of the SAB or BOD member of Applied Biomath, RareCyte Inc. and Glencoe Software, which distributes a commercial version of the OMERO database; P.K.S. is also a member of the NanoString SAB. In the last 5 years, the Sorger laboratory has received research funding from Novartis and Merck. Sorger declares that none of these relationships have influenced the content of this manuscript. S. Santagata is a consultant for RareCyte Inc. A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and, until 31 July 2020, was an SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. Since 1 August 2020, A.R. has been an employee of Genentech. L.M.C. is a paid consultant for Cell Signaling Technologies, AbbVie Inc. and Shasqi Inc.; received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., Innate Pharma, NanoString Technologies and Cell Signaling Technologies; is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc., Verseau Therapeutics, Cytomix Therapeutics, Inc. and Kineta Inc. and is a member of the Lustgarten Therapeutics Advisory working group. D.S. is a consultant for Roche Glycart AG. The other authors declare no outside interests.